Corrigendum to “Evaluation of Complication Rates after Breast Surgery Using Acellular Dermal Matrix: Median Follow-Up of Three Years”

Table 2

Indications for ADM implementation.

			Oncologic indication		Aesthetic indication
ADM	Product	BR with ADM (n)	BR with no capsular contracture	BR with capsular contracture	Primary augmentation	Secondary augmentation after capsular contracture	Secondary augmentation after aesthetic-related complications
HADM	Epiflex® / DIZG	15	1	3	9	2	0
PADM	Strattice® / LifeCell	21	6	8	5	2	0
BADM	Tutomesh® / rti surgical	16	2	5	3	2	4

Listing of kind of matrix used, name of product, number of breast reconstructions with certain ADMs, and indications for ADM usage (breast reconstruction (BR) with no capsular contracture, BR with capsular contracture, primary augmentation, secondary augmentation after capsular contracture, or secondary augmentation after aesthetic-related complications including IMF-loss and insufficient implant coverage with breast tissue). Oncologic patients made up 27% of the HADM group, 67% of the PADM group, and 44% of the BADM group; HADM: human ADM, PADM: porcine ADM, and BADM: bovine ADM; denotes no history of radiotherapy; denote history of radiotherapy; denote primary augmentation in cases with large breasts; denote loss of IMF.